MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Asymptomatic Gaucher disease presented as Parkinsonism in 61 years old patient.

    E. Basha, E. Ranxha, J. Tana (Tirana, Albania)

    Objective: Gaucher disease is an inherited disease caused by a mutation in the glucocerebrosidase gene, causing visceral, hematologic, and skeletal involvement. [1] [2] We report…
  • 2023 International Congress

    Dysconnectivity Profiles of Raphe Nuclei in Parkinson’s Disease: From Prodromal to Advanced Stage

    W. Junling, S. Junyan, Z. Dongling, C. Lili, W. Tao (Beijing, China)

    Objective: To investigate the functional connectivity changes of dorsal raphe (DR) and median raphe (MR) nucleus in patients with PD from the prodromal to advanced…
  • 2023 International Congress

    Psilocybin therapy for depression and anxiety associated with Parkinson’s disease: a pilot study (NCT04932434)

    E. Bradley, K. Sakai, G. Fernandes, C. Ludwig, M. Bock, J. Ostrem, C. Tanner, A. O'Donovan, P. Finley, Z. Busby, A. Mckernan, R. Zuzuarregui, A. Penn, A. Wang, A. Theberge, R. Rosen, J. Woolley (San Francisco, USA)

    Objective: To investigate the safety, tolerability, feasibility, and preliminary efficacy of moderate and high dose psilocybin treatment with psychotherapeutic support for comorbid Parkinson's disease (PD)…
  • 2023 International Congress

    Effects of physical exercise interventions on cognitive function in Parkinson’s disease: an updated systematic review and meta-analysis of randomized controlled trials

    R. Kim, JS. Jun, N. Kang (Incheon, Republic of Korea)

    Objective: To determine whether physical exercise interventions can improve cognitive function, including overall performance and specific domains, in patients with Parkinson’s disease (PD) and to…
  • 2023 International Congress

    The natural history of Parkinson’s disease in LRRK2 G2019S carriers

    M. Kmiecik, D. Coker, K. Heilbron, S. Aslibekyan, J. Shelton, P. Cannon, L. Norcliffe-Kaufmann (Sunnyvale, USA)

    Objective: To document differences between the evolution of self-reported symptoms and prodromal markers in LRRK2 G2019S carriers and non-carriers with and without Parkinson’s Disease (PD).…
  • 2023 International Congress

    Can very early levodopa prevent self-injury in Lesch-Nyhan Disease?

    J. Visser, O. Chorin, H. Jinnah (Nijmegen, Netherlands)

    Objective: To determine whether levodopa treatment starting at a very young age can prevent the development of the full clinical phenotype in Lesch-Nyhan disease. Background:…
  • 2023 International Congress

    Severe tacrolimus-induced parkinsonism after kidney transplantation

    N. Riemersma, D. Kremer, R. Prak, F. Huser, M. Vander Stouwe, C. Vroomen, S. Bakker (Groningen, Netherlands)

    Objective: To describe a kidney transplant recipient with severe tacrolimus-induced parkinsonism. Background: Kidney transplant recipients have to adhere to strict immunosuppressive regimens, which generally include…
  • 2023 International Congress

    Longitudinal free-water changes in dementia with Lewy bodies

    S. Chiu, R. Chen, W. Wang, M. Armstrong, B. Boeve, K. Kantarci, D. Vaillancourt (Gainesville, USA)

    Objective: To characterize longitudinal diffusion microstructural changes in individuals with dementia with Lewy bodies (DLB). Background: Diffusion-weighted MRI (dMRI) examines tissue microstructure integrity in vivo.…
  • 2023 International Congress

    Drivers of longitudinal healthcare cost in Parkinson Disease

    S. Neo, SW. Goh, ES. Saffari, AB. Zhan, HL. Ng, W. Li, R. Hoe, Z. Xu, KY. Tay, WL. Au, LCS. Tan (Singapore, Singapore)

    Objective: To identify associations between baseline patient and disease characteristics, and longitudinal healthcare costs in Parkinson disease (PD). Background: Disease prevalence, disability-adjusted life-years, and PD…
  • 2023 International Congress

    Neurological symptom severity in Wilson disease is associated with increased white matter mean diffusivity

    A. Hausmann, S. Kannenberg, C. Hartmann, J. Caspers, C. Rubbert, A. Schnitzler (Duesseldorf, Germany)

    Objective: To evaluate the relationship between white matter (WM) changes and neurological impairment in Wilson disease (WD). Background: Neuroimaging biomarkers derived from diffusion tensor imaging…
  • « Previous Page
  • 1
  • …
  • 64
  • 65
  • 66
  • 67
  • 68
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley